當(dāng)前位置：   首頁 > 需求大廳

 >  特色服務(wù) 

本公司目前擁有種植基地，目前擁有多個(gè)品種種植的技術(shù)，現(xiàn)需要進(jìn)行市場(chǎng)調(diào)研，尋求中藥材市場(chǎng)流通信息： 1.最好是擁有全套產(chǎn)品的中藥材市場(chǎng)供應(yīng)信息 2.每一個(gè)中藥材品種里面至少包含：產(chǎn)地、價(jià)格、產(chǎn)量、品質(zhì)、下游應(yīng)用廠家信息 3.具體品種可以私聊 4.價(jià)格面議   [更多]

和藥品原廠說明書 屬性一致，形成EXECL文檔，一個(gè)藥品一行，屬性項(xiàng)就X軸排開，，   [更多]

尋人查找一份日本藥品通用名和中文藥物名、英文名對(duì)照的數(shù)據(jù)表，要求內(nèi)容權(quán)威可信，信息及時(shí)更新（最新），藥品包含全面，經(jīng)核實(shí)后內(nèi)容準(zhǔn)確的，可獲得200元。具體要求如下 1：以日本藥品為準(zhǔn)，包含絕大部分藥物（如在日本上市，注冊(cè)，等），藥物全面，且錯(cuò)誤率在1%以下。 2：不能簡(jiǎn)單的在百度中下載文件來充數(shù)；因?yàn)椴蛔鎏幚?，這些文件質(zhì)量上還達(dá)不到要求。 3：所謂的藥品名都是指的藥品通用名，不是商品名，或者化學(xué)成份名稱。 如果只有日文中文對(duì)照或者日文英文對(duì)照，即可獲得100元。   [更多]

各位智友：本人因檢測(cè)需要，求分享歐洲藥典10.0檢測(cè) General Chapters部分。應(yīng)包括以下內(nèi)容 2.2.32. Loss on drying 2.4.16. Total ash 2.8.1 Ash insoluble in hydrochloric acid 2.8.2 FOREIGN MATTER 2.2.13 WATER 2.8.4 SWELLING INDEX 2.8.15 BITTERNESS VALUE Appendix XI B1. Ethanol-soluble Extractive Appendix XI B2. Water-soluble Extractive   [更多]

本人由于研發(fā)需要，現(xiàn)想求購(gòu)全套中藥材生產(chǎn)基地信息，如果可以提供全套信息，價(jià)格面議，如果可以提供具體品種的中國(guó)種植基地信息，通過驗(yàn)證齊全且真實(shí)的，每個(gè)品種可以獲得500元信息服務(wù)獎(jiǎng)勵(lì)   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,”?International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010.?View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,”?American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011.?View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo?release of ciprofloxacin from ophthalmic formulations,”?International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011.?View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德國(guó)藥典   [更多]

當(dāng)心血管疾病（心臟病或中風(fēng)）確診后，醫(yī)生會(huì)提供治療建議，但病人的決定是至關(guān)重要的。美國(guó)心臟協(xié)會(huì)（AHA）與 以病人為中心的成果研究所（PCORI）合作，網(wǎng)絡(luò)征集文章。你可以是患者，社區(qū)志愿者，家庭成員或任何人，只要你有這方面的親身經(jīng)驗(yàn)。根據(jù)你的情況來闡述患者的治療決策是怎樣做出的，例如：對(duì)壽命的影響，對(duì)生活質(zhì)量的影響，費(fèi)用，或其他？同時(shí)關(guān)心過程的完整性，時(shí)間，等等。。。 “請(qǐng)于2016年6月9日之前將稿件上傳到：https://www.innocentive.com/ar/workspace/challengeDetail?challenge=9933835“ THE CHALLENGE Treatment of heart disease and stroke often requires patients and their families to make many decisions on how to move forward after a cardiac event. Specifically, AHA and PCORI are interested in learning about the “decisional dilemmas” you face – your insights will help guide future research to improve heart health. Based on the input from you and others in the patient and caregiver community, we will identify important concerns and use the perspectives to target research towards what matters most. Despite multiple available treatment options that your physician may describe, you may not always know which option is right/best for you. Tell us about the most difficult decision that you or your family faced when evaluating treatment options for heart disease or stroke. In addition, we would like to understand more about what you considered most important when making this choice or decision. Please pick your top three choices and tell us why they are important to you and your family: Side effects of the treatment Complexity of treatment plan Difficulty in adhering to a treatment Impact on my quality of life Potential to prolong my life Whether the best option for me is selected based on research of people similar to me (personal characteristics such as my age, race and gender) Whether my family history and genetic makeup would influence the effectiveness of a given option Whether a trusted source recommended a specific option The financial impact of the options for me and my family Other:________ Any submission should address the following Submission Requirements: The submission can be from anyone (patient, caregiver, family member, or other)   [更多]

Good Clinical Practice: A Question & Answer Reference Guide 2018 (Electronic)，電子版，要2018年版   [更多]

信息要求：國(guó)內(nèi)外醫(yī)藥論壇、會(huì)議中發(fā)布的文件，包括但不限于PPT、PDF、圖片等，內(nèi)容以新藥信息為主提交稿件要求：1，文件需滿足在一年內(nèi)公布（如在2024年11月1日交稿，文件公布日期需在2023年11月1日之后）；2，稿件中有明確企業(yè)、藥品（項(xiàng)目）、研發(fā)階段、治療領(lǐng)域（適應(yīng)癥）等信息；3，交稿內(nèi)容以附件形式提交；4，以一個(gè)附件為單位，可提交多個(gè)，按單位結(jié)算，單價(jià)100元/個(gè)；驗(yàn)收標(biāo)準(zhǔn)：按要求投遞信息后，經(jīng)我方核實(shí)與已獲取到的信息不重復(fù)，即可獲取賞金。   [更多]

鹽酸多佐胺滴眼液 20000532   [更多]